{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicvh3ss3q2acytc2itnqgi5dmevycgs2oqv6r4gbe4xdzm77fm724",
    "uri": "at://did:plc:k7h5fn3kdhjpj37pc6yhno2o/app.bsky.feed.post/3mkwutri6flc2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreifsje3vp5anfmumgchegy6tz6h3xkhszn3zae33z35imr4dtktiyu"
    },
    "mimeType": "image/jpeg",
    "size": 130568
  },
  "path": "/article/why-the-fda-rejected-a-breakthrough-melanoma-drug/",
  "publishedAt": "2026-05-02T15:20:00.000Z",
  "site": "https://www.scientificamerican.com",
  "textContent": "The FDA rejected the promising skin cancer drug RP1 twice, leaving many puzzled and worried about what this means for other drug approvals",
  "title": "Why the FDA rejected a ‘breakthrough’ melanoma drug"
}